(Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and ...
GSK has news on that front today, as well, reporting that the phase 2/3 COSTAR trial of Jemperli with experimental TIM-3 antagonist cobolimab will move into the phase 3 stage on the advice of its ...
AnaptysBio reports positive Phase 2b results for rosnilimab in rheumatoid arthritis, with data for ulcerative colitis anticipated in Q4 2025. AnaptysBio, Inc. announced positive results from a ...
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...
14d
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever ...
With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...
Format – Presentation and one-on-one investor meetings Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT Live webcasts of the fireside chats and presentation will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback